Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed · Phase 2

Conditions studied: Glaucoma, Open-Angle, Ocular Hypertension

In brief

This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.

Key facts

Study ID

NCT01291108

Run by

Allergan

People needed

125

Starts

2011-04-01

Expected to finish

2011-10-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of primary open-angle glaucoma or ocular hypertension in each eye
• Requires bilateral treatment with an IOP-lowering medication
• Best corrected visual acuity of 20/100 or better in each eye

You may not qualify if…

• Use of oral, intramuscular, intravenous or topical ophthalmic corticosteroids within 2 months
• Inability to fast for up to 10 hours
• Prior refractive laser surgery (eg, LASIK, radial keratectomy, photorefractive keratectomy)
• Intraocular surgery or IOP-lowering laser surgery (eg, laser trabeculoplasty) within 6 months
• Current or anticipated use of artificial tears or any ocular medications aside from study medications during study
• Anticipated wearing of contact lenses during study

Where it is running

• Study site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.